blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP1928867

EP1928867 - 2-AMINOETHOXYACETIC ACID DERIVATIVES AND THEIR USE IN TREATING THROMBOEMBOLIC DISORDERS [Right-click to bookmark this link]
StatusPatent revoked
Status updated on  23.03.2022
Database last updated on 03.04.2025
Most recent event   Tooltip25.03.2022Revocation of patentpublished on 27.04.2022  [2022/17]
Applicant(s)For all designated states
Bayer Intellectual Property GmbH
Alfred-Nobel-Strasse 10
40789 Monheim / DE
[2012/39]
Former [2011/34]For all designated states
Bayer Pharma Aktiengesellschaft
Müllerstrasse 178
13353 Berlin / DE
Former [2009/38]For all designated states
Bayer Schering Pharma Aktiengesellschaft
Müllerstrasse 178
13353 Berlin / DE
Former [2009/37]For all designated states
Bayer Schering Pharma AG
Müllerstrasse 178
13353 Berlin / DE
Former [2008/24]For all designated states
Bayer HealthCare AG
51368 Leverkusen / DE
Inventor(s)01 / THOMAS, Christian, R.
Ilexweg 13
42111 Wuppertal / DE
02 / RÖHRIG, Susanne
Auf dem Kolksbruch 5
40724 Hilden / DE
03 / PERZBORN, Elisabeth
Am Tescher Busch 13
42327 Wuppertal / DE
 [2008/29]
Former [2008/24]01 / THOMAS, Christian, R.
Falkenberg 28
42113 Wuppertal / DE
02 / RÖHRIG, Susanne
Auf dem Kolksbruch 5
40724 Hilden / DE
03 / PERZBORN, Elisabeth
Am Tescher Busch 13
42327 Wuppertal / DE
Representative(s)Gille Hrabal Partnerschaftsgesellschaft mbB Patentanwälte
Postfach 18 04 09
40571 Düsseldorf / DE
[N/P]
Former [2014/43]Gille Hrabal
Postfach 18 04 09
40571 Düsseldorf / DE
Former [2013/21]BIP Patents
c/o Bayer Intellectual Property GmbH
Creative Campus Monheim
Alfred-Nobel-Straße 10
40789 Monheim / DE
Former [N/P]BIP Patents
c/o Bayer Intellectual Property GmbH
Creative Campus Monheim
Alfred-Nobel-Straße 10
DE-40789 Monheim / DE
Former [2013/01]BIP Patents
Creative Campus Monheim
Alfred-Nobel-Straße 10
40789 Monheim / DE
Former [2012/39]Bayer Intellectual Property GmbH
Creative Campus Monheim
Alfred-Nobel-Straße 10
40789 Monheim / DE
Application number, filing date06777189.914.09.2006
[2008/24]
WO2006EP08949
Priority number, dateDE2005104551823.09.2005         Original published format: DE102005045518
[2008/24]
Filing languageDE
Procedural languageDE
PublicationType: A1 Application with search report
No.:WO2007036306
Date:05.04.2007
Language:DE
[2007/14]
Type: A1 Application with search report 
No.:EP1928867
Date:11.06.2008
Language:DE
The application published by WIPO in one of the EPO official languages on 05.04.2007 takes the place of the publication of the European patent application.
[2008/24]
Type: B1 Patent specification 
No.:EP1928867
Date:22.05.2013
Language:DE
[2013/21]
Search report(s)International search report - published on:EP05.04.2007
ClassificationIPC:C07D413/12, A61K31/42, A61P7/00
[2008/24]
CPC:
C07D413/12 (EP,US); A61P7/00 (EP); A61P7/02 (EP)
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   NL,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2008/24]
Extension statesALNot yet paid
BANot yet paid
HRNot yet paid
MKNot yet paid
RSNot yet paid
TitleGerman:2-AMINOETHOXYESSIGSÄURE-DERIVATE UND IHRE VERWENDUNG ZUR BEHANDLUNG THROMBOEMBOLISCHER ERKRANKUNGEN[2008/24]
English:2-AMINOETHOXYACETIC ACID DERIVATIVES AND THEIR USE IN TREATING THROMBOEMBOLIC DISORDERS[2008/24]
French:DÉRIVÉS D'ACIDE 2-AMINOÉTHOXYACÉTIQUE ET UTILISATION POUR LE TRAITEMENT DE MALADIES THROMBOEMBOLIQUES[2013/03]
Former [2008/24]DERIVES D'ACIDE 2-AMINOETHOXYACETIQUE ET UTILISATION POUR LE TRAITEMENT DE MALADIES THROMBOEMBOLIQUES
Entry into regional phase23.04.2008National basic fee paid 
23.04.2008Designation fee(s) paid 
23.04.2008Examination fee paid 
Examination procedure23.04.2008Examination requested  [2008/24]
21.10.2009Despatch of a communication from the examining division (Time limit: M06)
20.04.2010Reply to a communication from the examining division
23.12.2010Observations by third parties
18.12.2012Communication of intention to grant the patent
08.02.2013Observations by third parties
05.04.2013Fee for grant paid
05.04.2013Fee for publishing/printing paid
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  21.10.2009
Opposition(s)Opponent(s)01  20.02.2014  25.02.2014  ADMISSIBLE
Gallafent, Antony Xavier
EuGen IP Limited
21 Bridge Street
Llandeilo SA19 6BN / GB
Opponent's representative
Isarpatent
Patent- und Rechtsanwälte Barth
Charles Hassa Peckmann & Partner mbB
Postfach 44 01 51
80750 München / DE
 02  21.02.2014  26.02.2014  ADMISSIBLE
KELTIE LLP
No.1 London Bridge
London SE1 9BA / GB
Opponent's representative
Moore, Michael Richard
Keltie LLP
No.1 London Bridge
London SE1 9BA / GB
 [N/P]
Former [2021/34]
Opponent(s)01  20.02.2014  25.02.2014  ADMISSIBLE
Gallafent, Antony Xavier
EuGen IP Limited
21 Bridge Street
Llandeilo SA19 6BN / GB
Opponent's representative
Isarpatent
Patent- und Rechtsanwälte Barth
Charkes Hassa Peckmann & Partner mbB
Postfach 44 01 51
80750 München / DE
 02  21.02.2014  26.02.2014  ADMISSIBLE
KELTIE LLP
No.1 London Bridge
London SE1 9BA / GB
Opponent's representative
Moore, Michael Richard
Keltie LLP
No.1 London Bridge
London SE1 9BA / GB
Former [2019/18]
Opponent(s)01  20.02.2014  25.02.2014  ADMISSIBLE
Gallafent, Antony Xavier
EuGen IP Limited
21 Bridge Street
Llandeilo SA19 6BN / GB
Opponent's representative
Gallafent, Alison
HGF Limited
Saviour House
9 St Saviourgate
GB-York YO1 8NQ / GB
 02  21.02.2014  26.02.2014  ADMISSIBLE
KELTIE LLP
No.1 London Bridge
London SE1 9BA / GB
Opponent's representative
Moore, Michael Richard
Keltie LLP
No.1 London Bridge
London SE1 9BA / GB
Former [2016/22]
Opponent(s)01  20.02.2014  25.02.2014  ADMISSIBLE
Gallafent, Antony Xavier
EuGen IP Limited
21 Bridge Street
Llandeilo SA19 6BN / GB
Opponent's representative
Gallafent, Alison
Alison Gallafent Ltd
21 Bridge St
Llandeilo SA19 6BN / GB
 02  21.02.2014  26.02.2014  ADMISSIBLE
KELTIE LLP
No.1 London Bridge
London SE1 9BA / GB
Opponent's representative
Moore, Michael Richard
Keltie LLP
No.1 London Bridge
London SE1 9BA / GB
Former [2016/21]
Opponent(s)01  20.02.2014  25.02.2014  ADMISSIBLE
Gallafent, Antony Xavier
EuGen IP Limited
21 Bridge Street
Llandeilo SA19 6BN / GB
Opponent's representative
Gallafent, Alison
Olswang LLP
90 High Holborn
London WC1V 6XX / GB
 02  21.02.2014  26.02.2014  ADMISSIBLE
KELTIE LLP
No.1 London Bridge
London SE1 9BA / GB
Opponent's representative
Moore, Michael Richard
Keltie LLP
No.1 London Bridge
London SE1 9BA / GB
Former [2016/01]
Opponent(s)01  20.02.2014  25.02.2014  ADMISSIBLE
Gallafent, Antony Xavier
EuGen IP Limited
21 Bridge Street
Llandeilo SA19 6BN / GB
Opponent's representative
Gallafent, Alison
Alison Gallafent Ltd
21 Bridge St
Llandeilo SA19 6BN / GB
 02  21.02.2014  26.02.2014  ADMISSIBLE
KELTIE LLP
No.1 London Bridge
London SE1 9BA / GB
Opponent's representative
Moore, Michael Richard
Keltie LLP
No.1 London Bridge
London SE1 9BA / GB
Former [2015/33]
Opponent(s)01  20.02.2014  25.02.2014  ADMISSIBLE
Gallafent, Antony Xavier
EuGen IP Limited
21 Bridge Street
Llandeilo SA19 6BN / GB
 02  21.02.2014  26.02.2014  ADMISSIBLE
KELTIE LLP
No.1 London Bridge
London SE1 9BA / GB
Opponent's representative
Moore, Michael Richard
Keltie LLP
No.1 London Bridge
London SE1 9BA / GB
Former [2014/20]
Opponent(s)01  20.02.2014  25.02.2014  ADMISSIBLE
Gallafent, Antony Xavier
4 George St
Llandeilo SA 19 6AS / GB
 02  21.02.2014  26.02.2014  ADMISSIBLE
KELTIE LLP
Fleet Place House
2 Fleet Place
London EC4M 7ET / GB
Opponent's representative
Moore, Michael Richard
Keltie LLP
Fleet Place House
2 Fleet Place
London EC4M 7ET / GB
Former [2014/14]
Opponent(s)01  20.02.2014  25.02.2014  ADMISSIBLE
Gallafent, Antony Xavier
4 George St
Llandeilo SA 19 6AS / GB
 02  21.02.2014  26.02.2014  ADMISSIBLE
KELTIE LLP
Fleet Park House
2 Fleet Place
London EC4M 7ET / GB
Opponent's representative
Moore, Michael Richard
Keltie LLP
Fleet Place House
2 Fleet Place
London EC4M 7ET / GB
deletedDeletion: Legal effect of rejection of opposition [ N /P ]
28.03.2014Invitation to proprietor to file observations on the notice of opposition
07.11.2014Reply of patent proprietor to notice(s) of opposition
16.07.2015Cancellation of oral proceeding that was planned for 03.11.2015
03.11.2015Date of oral proceedings
11.12.2015Cancellation of oral proceeding that was planned for 22.01.2016
22.01.2016Date of oral proceedings
30.06.2016Date of oral proceedings
22.08.2016Despatch of minutes of oral proceedings
22.08.2016Date of despatch of rejection of opposition
10.03.2022Legal effect of revocation of patent [2022/17]
22.03.2022Despatch of communication that the patent will be revoked
Appeal following opposition08.10.2016Appeal received No.  T2323/16
23.12.2016Statement of grounds filed
10.03.2022Result of appeal procedure: REVOCATION OF PATENT AT PROPRIETOR'S REQUEST
22.03.2022Despatch of the decision of the Board of Appeal
21.10.2016Appeal received No.  T2323/16
22.12.2016Statement of grounds filed
10.03.2022Result of appeal procedure: REVOCATION OF PATENT AT PROPRIETOR'S REQUEST
22.03.2022Despatch of the decision of the Board of Appeal
10.03.2022Date of oral proceedings
Fees paidRenewal fee
30.09.2008Renewal fee patent year 03
30.09.2009Renewal fee patent year 04
30.09.2010Renewal fee patent year 05
30.09.2011Renewal fee patent year 06
12.09.2012Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU14.09.2006
CY22.05.2013
CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
LT22.05.2013
LV22.05.2013
MC22.05.2013
NL22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
TR22.05.2013
BG22.08.2013
GR23.08.2013
AT14.09.2013
IE14.09.2013
LU14.09.2013
IS22.09.2013
PT23.09.2013
BE30.09.2013
CH30.09.2013
LI30.09.2013
[2015/34]
Former [2015/32]CY22.05.2013
CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
LT22.05.2013
LV22.05.2013
MC22.05.2013
NL22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
TR22.05.2013
BG22.08.2013
GR23.08.2013
AT14.09.2013
IE14.09.2013
IS22.09.2013
PT23.09.2013
BE30.09.2013
CH30.09.2013
LI30.09.2013
Former [2015/30]CY22.05.2013
CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
LT22.05.2013
LV22.05.2013
MC22.05.2013
NL22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
BG22.08.2013
GR23.08.2013
AT14.09.2013
IE14.09.2013
IS22.09.2013
PT23.09.2013
BE30.09.2013
CH30.09.2013
LI30.09.2013
Former [2015/12]CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
LT22.05.2013
LV22.05.2013
MC22.05.2013
NL22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
BG22.08.2013
GR23.08.2013
AT14.09.2013
IE14.09.2013
IS22.09.2013
PT23.09.2013
BE30.09.2013
CH30.09.2013
LI30.09.2013
Former [2014/34]CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
LT22.05.2013
LV22.05.2013
MC22.05.2013
NL22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
BG22.08.2013
GR23.08.2013
IE14.09.2013
IS22.09.2013
PT23.09.2013
BE30.09.2013
CH30.09.2013
LI30.09.2013
Former [2014/33]CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
LT22.05.2013
LV22.05.2013
MC22.05.2013
NL22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
BG22.08.2013
GR23.08.2013
IE14.09.2013
IS22.09.2013
PT23.09.2013
Former [2014/20]CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
LT22.05.2013
LV22.05.2013
MC22.05.2013
NL22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
BG22.08.2013
GR23.08.2013
IS22.09.2013
PT23.09.2013
Former [2014/14]CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
LT22.05.2013
LV22.05.2013
NL22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
BG22.08.2013
GR23.08.2013
IS22.09.2013
PT23.09.2013
Former [2014/11]CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
LT22.05.2013
LV22.05.2013
PL22.05.2013
RO22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
BG22.08.2013
GR23.08.2013
IS22.09.2013
PT23.09.2013
Former [2014/10]CZ22.05.2013
DK22.05.2013
EE22.05.2013
FI22.05.2013
LT22.05.2013
LV22.05.2013
PL22.05.2013
SE22.05.2013
SI22.05.2013
SK22.05.2013
BG22.08.2013
GR23.08.2013
IS22.09.2013
PT23.09.2013
Former [2014/09]DK22.05.2013
EE22.05.2013
FI22.05.2013
LT22.05.2013
LV22.05.2013
PL22.05.2013
SE22.05.2013
SI22.05.2013
BG22.08.2013
GR23.08.2013
IS22.09.2013
PT23.09.2013
Former [2014/02]FI22.05.2013
LT22.05.2013
LV22.05.2013
PL22.05.2013
SE22.05.2013
SI22.05.2013
BG22.08.2013
GR23.08.2013
IS22.09.2013
PT23.09.2013
Former [2013/50]FI22.05.2013
LT22.05.2013
PL22.05.2013
SE22.05.2013
SI22.05.2013
BG22.08.2013
GR23.08.2013
IS22.09.2013
PT23.09.2013
Former [2013/49]FI22.05.2013
LT22.05.2013
SE22.05.2013
SI22.05.2013
GR23.08.2013
IS22.09.2013
PT23.09.2013
Former [2013/48]LT22.05.2013
IS22.09.2013
PT23.09.2013
Former [2013/47]LT22.05.2013
PT23.09.2013
Cited inInternational search[YD]WO0147919  (BAYER AG [DE], et al) [YD] 1-12 * abstract * * examples 152,180 * * claim - *;
 [YD]DE10105989  (BAYER AG [DE]) [YD] 1-12 * abstract * * example - * * claim - *
otherWO2005068456
    - PERZBORN E. ET AL, "IN VITRO AND IN VIVO STUDIES OF THE NOVEL ANTITHROMBOTIC AGENT BAY 59-7939-AN ORAL, DIRECT FACTOR XA INHIBITOR", JOURNAL OF THROMBOSIS AND HAEMOSTASIS, (2005), vol. 3, pages 514 - 521, XP009050814

DOI:   http://dx.doi.org/10.1111/j.1538-7836.2005.01166.x
    - WEINZ C. ET AL, "In vitro metabolism of bay 59-7939-an oral, direct factor Xa inhibitor, abstr.nr. 195", DRUG METABOLISM REVIEWS, (2004), vol. 36, page 98, XP003030930
    - LANG D. ET AL, "In vitro metabolism of Rivaroxaban, an oral, direct factor Xa inhibitor, in liver microsomes and hepatocytes of rats, dogs, and humans", DRUG METAB. DISPOS., (2009), vol. 37, no. 5, pages 1046 - 1055, XP003030931

DOI:   http://dx.doi.org/10.1124/dmd.108.025551
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.